FDA Approves Crysvita (burosumab-twza) for X-Linked Hypophosphatemia

April 17, 2018 -- The U.S. Food and Drug Administration today approved Crysvita (burosumab), the first drug approved to treat adults and children ages 1 year and older with x-linked hypophosphatemia (XLH), a rare, inherited form of rickets. XLH...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news